Windtree Therapeutics Q2 2024 GAAP EPS $(20.91) Misses $(2.27) Estimate
Portfolio Pulse from Benzinga Newsdesk
Windtree Therapeutics reported a significant quarterly loss of $(20.91) per share, missing the analyst consensus estimate of $(2.27) by a large margin.
August 20, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Windtree Therapeutics reported a Q2 2024 loss of $(20.91) per share, significantly missing the analyst estimate of $(2.27). This large miss could negatively impact investor sentiment and the stock price in the short term.
The reported loss per share was significantly worse than expected, which is likely to lead to negative investor sentiment and a decrease in stock price. The magnitude of the miss (821.15%) suggests a severe underperformance, increasing the likelihood of a negative market reaction.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100